Villere ST Denis J & Co. LLC Sells 2,595 Shares of Stryker Corporation $SYK

Villere ST Denis J & Co. LLC reduced its stake in shares of Stryker Corporation (NYSE:SYK) by 3.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 75,264 shares of the medical technology company’s stock after selling 2,595 shares during the quarter. Stryker accounts for approximately 2.7% of Villere ST Denis J & Co. LLC’s holdings, making the stock its 11th biggest position. Villere ST Denis J & Co. LLC’s holdings in Stryker were worth $24,731,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in shares of Stryker by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after buying an additional 133,892 shares during the last quarter. State Street Corp grew its position in Stryker by 2.1% during the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after buying an additional 311,507 shares in the last quarter. Geode Capital Management LLC grew its position in Stryker by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock worth $2,636,238,000 after buying an additional 69,851 shares in the last quarter. Wellington Management Group LLP increased its stake in Stryker by 22.6% during the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after acquiring an additional 1,198,665 shares during the period. Finally, Alliancebernstein L.P. raised its holdings in Stryker by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after acquiring an additional 741,542 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Price Performance

NYSE:SYK traded up $2.75 during trading hours on Friday, reaching $329.86. The company had a trading volume of 2,724,614 shares, compared to its average volume of 2,471,298. The stock has a 50-day moving average of $310.12 and a two-hundred day moving average of $337.97. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87. The firm has a market capitalization of $126.46 billion, a PE ratio of 38.18, a PEG ratio of 2.10 and a beta of 0.77. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same quarter in the prior year, the company earned $2.84 earnings per share. The business’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts forecast that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s payout ratio is 40.74%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. The Goldman Sachs Group restated a “neutral” rating and set a $361.00 price objective on shares of Stryker in a research report on Friday, May 1st. BMO Capital Markets started coverage on shares of Stryker in a research note on Wednesday. They set an “outperform” rating and a $369.00 price target on the stock. Wells Fargo & Company lowered their price target on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Barclays dropped their price objective on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Finally, UBS Group lowered their target price on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average price target of $392.87.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.